---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-054950"
form_type: "8-K"
ticker: "JANX"
cik: "0001817713"
company_name: "Janux Therapeutics, Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T12:29:36.809740+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Janux Therapeutics Q1 2024: Cash $651.8M; net loss $14.8M; trials ongoing

## Summary
- Cash and short-term investments $651.8M as of March 31, 2024, up from $344.0M at Dec 31, 2023.
- Net loss $14.8M for Q1 2024, improved from $17.5M in Q1 2023; R&D expenses $14.1M vs $15.9M.
- Enrollment ongoing in Phase 1 trials for JANX007 (PSMA-TRACTr in mCRPC) and JANX008 (EGFR-TRACTr in solid tumors).
- JANX007 data update and expansion cohort doses anticipated in 2H 2024; JANX008 data expected in 2025.

## SEC filing metadata
- accession: 0000950170-24-054950
- form_type: 8-K
- ticker: JANX
- cik: 0001817713
- company_name: Janux Therapeutics, Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817713/000095017024054950/0000950170-24-054950-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817713/000095017024054950/janx-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-054950
- JSON: https://secwatch.observer/filing/0000950170-24-054950.json
- Plain text: https://secwatch.observer/filing/0000950170-24-054950.txt

## Key facts
- Earnings Releases
  Janux Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income Net loss of $14.8 million.
  - Period: first quarter ended March 31, 2024
  - Net income: Net loss of $14.8 million
  - Result: reported results
  source text: Janux Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the three months ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817713/000095017024054950/0000950170-24-054950-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.